GNAS and neoplasm: The prevalence of GNAS mutations in ‘MS + Bone’ and ‘MT + Tumor’ subgroups was 67% (95% CI = 42%–88%; n = 187) and 64% (95% CI = 24%–95%; n = 15; two studies), respectively.